Articles tagged with Drug Discovery
A recent study has identified a promising solution to combat resistance to protein degraders, which are a novel approach in drug discovery. The researchers found that the drug RBS-10 selectively removes resistant cells by targeting the enzyme NQO1, which is overexpressed in these cells.
Researchers at Insilico Medicine have identified MYT1 as a promising therapeutic target for breast and gynecological cancers. A series of novel, potent, and highly selective inhibitors specifically targeting MYT1 were discovered using AI-driven generative biology and chemistry engine.
Insilico Medicine has discovered a novel PHD inhibitor for treating anemia using its AI-powered generative chemistry platform Chemistry42. The compound demonstrated favorable ADMET and PK profiles in animal models, showing promise for further investigations.
The CACHE Challenge series has identified seven promising molecules with potential for new, more effective drugs for familial Parkinson's disease. The open science competition, funded by The Michael J. Fox Foundation and Conscience, used AI to predict hits and validated experimental results.
Researchers developed a platform combining automated experiments with AI to predict chemical reactivity, greatly accelerating the design process for new drugs. A machine learning model predicts where molecules will react and how reaction sites vary under different conditions, enabling precise tweaks to complex molecules.
A new catalyst developed by researchers at Nagoya University successfully synthesized a key intermediate for the incontinence drug oxybutynin in 5-30 minutes, significantly faster than existing methods. The discovery represents a major advance in chiral drug synthesis and holds great promise for future drug discovery efforts.
A global study has identified over 200 genes linked to depression, including 50 new genetic loci and 205 novel genes. The research also suggests potential for drug repurposing and highlights the need for more diverse genetic datasets to develop effective treatments.
The University of Rochester is establishing a new NIH-funded center focused on developing FDA-qualified drug development tools related to barrier functions in disease. Researchers will create microphysiological systems with ultrathin membranes of human cells, aiming to reduce animal trials and improve drug efficacy.
Researchers discovered new antibiotic molecules targeting Mycobacterium tuberculosis, reducing its pathogenicity. These substances also enhance the activity of conventional antibiotics like ethionamide, offering a renewed treatment approach.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
A new synthetic antibiotic teixobactin has been shown to be highly effective against 'superbugs' such as MRSA and bacterial biofilms, which are associated with serious chronic infections. The study's findings provide promising hope for the development of new treatments against multidrug-resistant bacteria and biofilm-related infections.
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
Researchers develop a novel protein killer and discover a new ligase for PROTACs, which can specifically target and degrade pathological proteins in specific tissues. This breakthrough could enable the targeted degradation of proteins in tumors.
Researchers at the University of Bath have created a novel bacterial system to mass-produce cyclic proteins and peptides, addressing a significant bottleneck in the development of new therapeutic treatments. By harnessing the natural cyclization process from the Oldenlandia flower, they improved heat and chemical stability, as well as ...
A Phase II clinical trial has demonstrated that fosravuconazole is effective in treating mycetoma, a chronic disabling disease. The new oral treatment has been shown to have significant advantages over existing treatments, including a lower pill burden and minimal interactions with other medications.
This special collection in SLAS Discovery highlights the significant impact of high-content imaging in basic and translational research. Researchers have made advancements in cell painting and phenotypic profiling, offering new therapeutic approaches for diseases such as Gaucher's.
A small molecule called YM022 has been discovered to block aversive memory formation in mice, offering a new direction for developing anti-depressants. The study found that YM022 suppressed neuroplasticity-caused aversive memory formation and reduced depressive behaviors in mice.
Researchers have discovered two new cofactorless oxygenases, TnmJ and TnmK2, which enable bacteria to produce compounds for targeting and breaking up DNA. This breakthrough offers a potentially easier way to study and manufacture complex natural chemicals, including those that could become medicines.
Researchers have identified a crucial biological trigger of Huntington's disease, finding that methylation converts an important protein into waste. By targeting this process, they may develop effective therapies for other neurodegenerative diseases.
Researchers developed a waterproof device that captures and enriches dissolved compounds in seawater, revealing diverse elemental compositions and unknown molecular structures, with potential applications for drug discovery and ecosystem health monitoring.
New study reveals that microtubule poisons effectively treat cancer by causing abnormal cell division, leading to tumor cell death. The findings contradict decades-long assumptions about the mechanism of action of these drugs.
Scientists at Nagoya University developed a new gastric acid inhibitor with a binding affinity nearly 10 times higher than existing drugs. The AI-driven approach led to the creation of compound DQ-18, which exhibits stronger binding to the gastric proton pump.
Cleveland Clinic is selected by Wellcome Leap to lead two quantum computing research projects in collaboration with IBM Quantum and Algorithmiq. The projects aim to accelerate the development of quantum computing applications for healthcare, with a focus on protein structure prediction and photon-drug interactions in cancer treatment.
Researchers at Scripps Research have identified promising cancer drug targets by combining precise genome engineering and protein activity profiling. They used base editing to alter thousands of possible drug targets, then integrated the data with chemical proteomic information to pinpoint hundreds of potential targets.
A special issue of SLAS Discovery magazine highlights the Virginia Drug Discovery Consortium's efforts to promote drug discovery and development in Virginia. The issue features original research, protocols, and perspectives on novel technologies and approaches for understanding and treating human disease.
Researchers developed a new technology to test new drugs against liver diseases by recreating the real human liver environment. The model consists of live liver cells in an artificial blood vessel system, allowing for controlled testing and monitoring.
Insilico Medicine has identified 9 potential dual-purpose targets against aging and 14 major age-related diseases using Microsoft BioGPT. The proposed genes include CCR5 and PTH, which have not been previously correlated to the aging process.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Researchers at University of California - Riverside uncover COVID's Achilles heel - its dependence on key human proteins. By understanding how the virus interacts with human cells, a new class of antiviral medication may be developed to block replication and treatment.
Researchers at Mount Sinai identified the structure of a red blood cell transporter and how it interacts with drugs. They discovered novel compounds capable of blocking the transporter, potentially leading to new treatments for conditions like hemolytic anemias.
The August 2023 issue of SLAS Technology features original research articles on nanodiamonds, automated buffer exchange, and epidermal growth factor. A new scheduling method called SAGAS is proposed to optimize life science experiments in laboratory automation.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
A miniature human heart model, approximately half a grain of rice in size, has been developed to transform drug testing and cardiovascular research. This self-paced, multi-chambered model provides real-time measurements of essential parameters, enabling unprecedented insights into heart function and diseases.
Researchers at Penn State have discovered a safe and efficient way to create cyclopropanes, key features in many drugs, using a previously undescribed chemical process. The new method uses visible light and common ingredients to transform alkenes into cyclopropanes with no carbene intermediate.
Insilico Medicine's inClinico platform uses generative AI to predict Phase II to Phase III clinical trial success with an accuracy of 79%. The tool has been validated in various studies and can provide valuable insights for investors and biotech/pharma companies.
Researchers at Insilico Medicine discovered novel inhibitors for salt-inducible kinase 2 (SIK2), a potential target for anti-inflammation and anti-cancer therapy. The findings were published in the July 13 edition of Bioorganic & Medicinal Chemistry, demonstrating the power of Insilico's Pharma.AI platform.
Researchers at NYU College of Dentistry developed a gene therapy that regulates sodium ion channel activity to alleviate chronic pain. By targeting the specific region where CRMP2 binds to NaV1.7, they were able to reduce sodium influx and quiet down neurons, providing relief from pain in cell and animal studies.
The latest issue of SLAS Discovery features novel technologies and approaches to develop and characterize chemical and biological tools for human disease treatment. The journal reports on high-throughput screening-related research, including fluorescence polarization assay use and glycomimetics.
Researchers at Tokyo University of Science successfully synthesized tanzawaic acid B in large amounts, paving the way for new antibiotic development. The breakthrough method could lead to creation of various compounds for pharmaceuticals, including new antibiotic candidates.
The study evaluates recent research on artificial intelligence-generated molecular structures from the perspective of medicinal chemists, recommending guidelines for assessing novelty and validity. Insilico Medicine's recommendations aim to improve the process of generating and evaluating novel AI-generated drugs.
Scientists used Insilico Medicine's generative AI platform to identify actionable drug targets for cystinosis and validate them in preclinical models. The study found that hyperactive mTOR signaling drives kidney tubular cell dysfunction, making it a targetable pathway.
Researchers at the University of Zurich have used AI to uncover the underlying cellular mechanism behind kidney disease in cystinosis. They identified a causal association between mTORC1 protein regulation and the disease, highlighting a promising therapeutic target.
Using MRI instead of CT with CTA alone in patients presenting to the ED with dizziness was associated with greater critical neuroimaging results and more frequent echocardiography. Patients with dizziness undergoing MRI showed a lower frequency of 90-day ED readmissions compared to those discharged after CT with CTA alone.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
A proof-of-concept study demonstrates the effectiveness of two supporting matrices in growing spheroids derived from patient cells for 3D drug sensitivity and resistance testing. This finding offers promising prospects for automating this process in drug testing.
Academic scientists will receive funding to establish a pleiotropic brain-penetrant small-molecule to impede glioblastoma and develop an epigenetic therapy for Prader-Willi syndrome. The TRxA program aims to bridge the drug development 'valley of death' and advance novel therapeutics from lab to clinical trials.
Researchers discovered crucial differences in venoms across the lifecycle of cone snails, using a new laboratory aquarium system to study juvenile stages. The findings reveal unique adaptations for hunting and venom composition, offering potential new drugs for pain medication and disease treatment.
Researchers have developed a new AI model that can quickly screen large libraries of potential drug compounds against target proteins. The ConPLex model uses language analysis to match potential drugs with proteins without needing to calculate molecular structures, enabling fast screening of over 100 million compounds per day.
Researchers developed a mass spectrometry method to analyze molecular glues and assess their relative strengths. The technique enables the elucidation of mechanisms through which these molecules stabilize protein interactions.
Researchers updated their protein localization prediction model, MULocDeep, to provide more targeted predictions for biological discoveries. The tool helps researchers design more effective experiments and advance scientific discoveries related to drug development and treating diseases like epilepsy.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers at Ohio State University developed an AI framework called G2 Retro to automatically generate chemical reactions for molecules. The framework was shown to cover a vast range of possible reactions and accurately predict the best synthesis routes, offering more efficient drug design options.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
Researchers found that T cells can self-activate by puckering their cell membrane, boosting function and slowing tumor growth in a mouse model. This discovery could inspire new anti-tumor therapeutics and provide insights into treating autoimmune diseases.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers from Integrated Biosciences developed an AI platform to discover novel senolytic compounds, a class of molecules targeting age-related processes. The platform identified three highly selective and potent compounds with favorable medicinal chemistry properties.
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Scripps Research scientists develop a new strategy to identify small molecules that can alter protein function, offering a promising path for discovering targeted cancer drugs. By comparing how mirror image versions of small molecules impact clusters of proteins, they identified potential new drug targets such as MY-1B and EV-96.
Researchers developed a high-throughput assay to analyze CAR-T cells' effects on 3D tumor spheroid models using plate-based image cytometry. This study demonstrates the potential benefits of this method for assessing potency, specificity, and location of CAR-T cells in relation to spheroids.